Immune responses provide clues for HIV vaccine development

Recent research has yielded new information about immune responses associated with — and potentially responsible for — protection from HIV infection, providing leads for new strategies to develop an HIV vaccine. Results from the RV144 trial, reported in 2009, provided the first signal of HIV vaccine efficacy: a 31 percent reduction in HIV infection among vaccinees. Since then, an international research consortium has been searching for molecular clues to explain why the vaccine showed this modest protective effect. (Mehr in: Cancer News — ScienceDaily)